X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Venezuelan Equine Encephalitis (VEE) vaccine is delivered with PharmaJet precision delivery, needle-free injection system resulted in humoral and cellular immune responses significant protection against disease and viremia.
Lead Product(s): VEE DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Lead Product(s): SCIB1,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: SCIB1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Scancell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The funding will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
Lead Product(s): Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: DTRA
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 18, 2023
Details:
Covidity (SCOV1 and SCOV2 vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Lead Product(s): SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases Product Name: COVIDITY
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Scancell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Phase II grant from the National Institutes of Health (NIH), to evaluate the immunogenicity of intradermal administration of human papillomavirus virus (HPV) vaccine using their Tropis intradermal (ID) Needle-free Injection System (NFIS).
Lead Product(s): HPV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding November 29, 2022
Details:
The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
Lead Product(s): Fractional Inactivated Poliovirus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: fIPV
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: USAID
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding October 24, 2022
Details:
Delivery of Venezuelan equine encephalitis DNA vaccine with PharmaJet Stratis® (Intramuscular – IM) or PharmaJet Tropis® (Intradermal – ID) Needle-free Injection System resulted in humoral and cellular immune responses significant protection against disease and viremia.
Lead Product(s): DNA-based Venezuelan Equine Encephalitis Virus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Military Health System Research Symposium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The DNA-Based COVID-19 vaccine is one of few vaccines worldwide targeting the Omicron variant, rather than the original strain of the virus.As DNA vaccines can be modified easily the vaccine can be quickly adapted to future variants.
Lead Product(s): DNA-based COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
CV7201 mRNA, is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein, can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe.
Lead Product(s): CV7201 mRNA
Therapeutic Area: Infections and Infectious Diseases Product Name: CV7201 mRNA
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: CureVac
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Phase 3 interim clinical trial data of their plasmid DNA vaccine ZyCoV-D, highlights the overall effectiveness and protective efficacy against COVID-19 in expanded age groups when administered intradermally with the Tropis® intradermal System.
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Zydus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
